Why is Quest Diagnostics stock sliding today?

Quest Diagnostics shares declined by 5.2% in post-market trading, settling at $232.12, following Medicare & Medicaid Services' release of preliminary reimbursement rate proposals. These proposals could reduce laboratory fee payments by as much as 15% starting January 1, 2027. The Centers for Medicare & Medicaid Services (CMS) based their announcement on data from over 6,400 laboratories, stating that Medicare had been overpaying labs by around 16% compared to private insurers.

They estimated that the realignment would save taxpayers approximately $1 billion annually. The regulatory blow hit Quest Diagnostics at a particularly unfortunate time, as the company had reached a new 52-week high of $248.84 earlier in the day, only to see those gains erased and more in after-hours trading. An analysis from Truist Securities, which maintained a Hold rating while increasing the price target to $260 from $250, offered little protection against the magnitude of the reimbursement risk.

Quest Diagnostics' core revenue model relies heavily on routine clinical testing volumes, making the proposed cuts directly related to the company's financial health. Labcorp, Quest's closest competitor and equally affected by the Clinical Laboratory Fee Schedule, also experienced a decline in stock price after the same regulatory announcement.

The broader U.S. equity market did not provide a significant cushion, with the S&P 500 remaining essentially flat, the Dow Jones rising marginally, and the Nasdaq barely changing. These factors combined, indicating that the drop in Quest Diagnostics' stock was driven entirely by the company-specific regulatory catalyst, not by any broader market shifts.

Quest Diagnostics' stock had already hit a fresh 52-week high before the after-hours sell-off, but the sudden threat to Medicare reimbursement created a perfect storm for a sharp correction. Lab tests and advocacy groups have about 30 days to provide formal comments on the preliminary rates, and the Centers for Medicare & Medicaid Services plans to finalize the CY2027 schedule in November 2026. This prolonged uncertainty is expected to weigh on the company's stock in the near term.